Cargando…

Negative trials in ovarian cancer: is there such a thing as too much optimism?

Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyawali, Bishal, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990052/
https://www.ncbi.nlm.nih.gov/pubmed/27594913
http://dx.doi.org/10.3332/ecancer.2016.ed58
Descripción
Sumario:Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results, the studies concluded optimistically in favor of the new agents under study. Using these examples, we point out the discrepancies and the risks of concluding optimistically based on statistical significance when the actual benefit is minimal. We also appeal against conducting large phase 3 trials that require significant resources without good phase 2 evidence for doing so.